NCT07153003
Efficacy And Safety Of Tramadol And Oxycodone Versus Oxycodone Monotherapy For Pain Control After Primary Total Knee And Total Hip Arthroplasty
Enrolling by Invitation
PHASE4Ages 18+InterventionalTreatmentMayo ClinicInvestigator-initiated
~560 participants
Updated 2026-03-18 on ClinicalTrials.gov
What's tested:OxycodoneTramadol and Oxycodone
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Cumulative opioid consumption during the first 30 days
Measured over 30 days
Conditions
Where it's being run
1 sites across 1 statesMinnesota1
Study leadership
- Charles P. Hannon, MD, MBA · PRINCIPAL_INVESTIGATOR · Mayo Clinic
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Primary TKA
Primary THA
Age \> 18 years
Exclusion
Age \< 18 years
Revision or partial TKA/THA
Pregnant or breast-feeding women
Simultaneous bilateral TKA/THA
Primary TKA/THA due to oncologic reason
Anaphylaxis to opioids
Renal or liver failure
Prior opioid use disorder/ substance use disorder
Opioid use within 3 months prior to surgery
Patients needing a translator and those with dementia or other cognitive deficits
Patients taking Monoamine Oxidase Inhibitor (MOAI) medications (phenelzine, tranylcypromine) or benzodiazepine medications (alprazolam, diazepam, lorazepam, etc)
What this trial measures
- Cumulative opioid consumption during the first 30 days30 days
Total amount of opioid medication taken for the first 30 days following surgery, reported in milligrams (mg)